118 related articles for article (PubMed ID: 10201821)
1. Potent, orally absorbed glucagon receptor antagonists.
de Laszlo SE; Hacker C; Li B; Kim D; MacCoss M; Mantlo N; Pivnichny JV; Colwell L; Koch GE; Cascieri MA; Hagmann WK
Bioorg Med Chem Lett; 1999 Mar; 9(5):641-6. PubMed ID: 10201821
[TBL] [Abstract][Full Text] [Related]
2. Pyrroles and other heterocycles as inhibitors of p38 kinase.
de Laszlo SE; Visco D; Agarwal L; Chang L; Chin J; Croft G; Forsyth A; Fletcher D; Frantz B; Hacker C; Hanlon W; Harper C; Kostura M; Li B; Luell S; MacCoss M; Mantlo N; O'Neill EA; Orevillo C; Pang M; Parsons J; Rolando A; Sahly Y; Sidler K; O'Keefe SJ
Bioorg Med Chem Lett; 1998 Oct; 8(19):2689-94. PubMed ID: 9873604
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a novel, non-peptidyl antagonist of the human glucagon receptor.
Cascieri MA; Koch GE; Ber E; Sadowski SJ; Louizides D; de Laszlo SE; Hacker C; Hagmann WK; MacCoss M; Chicchi GG; Vicario PP
J Biol Chem; 1999 Mar; 274(13):8694-7. PubMed ID: 10085108
[TBL] [Abstract][Full Text] [Related]
4. The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase.
Wilson KP; McCaffrey PG; Hsiao K; Pazhanisamy S; Galullo V; Bemis GW; Fitzgibbon MJ; Caron PR; Murcko MA; Su MS
Chem Biol; 1997 Jun; 4(6):423-31. PubMed ID: 9224565
[TBL] [Abstract][Full Text] [Related]
5. 6-Amino-2-(4-fluorophenyl)-4-methoxy-3- (4-pyridyl)-1H-pyrrolo[2, 3-b]pyridine (RWJ 68354): a potent and selective p38 kinase inhibitor.
Henry JR; Rupert KC; Dodd JH; Turchi IJ; Wadsworth SA; Cavender DE; Fahmy B; Olini GC; Davis JE; Pellegrino-Gensey JL; Schafer PH; Siekierka JJ
J Med Chem; 1998 Oct; 41(22):4196-8. PubMed ID: 9784093
[No Abstract] [Full Text] [Related]
6. Substituted imidazoles as glucagon receptor antagonists.
Chang LL; Sidler KL; Cascieri MA; de Laszlo S; Koch G; Li B; MacCoss M; Mantlo N; O'Keefe S; Pang M; Rolando A; Hagmann WK
Bioorg Med Chem Lett; 2001 Sep; 11(18):2549-53. PubMed ID: 11549467
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase.
Liverton NJ; Butcher JW; Claiborne CF; Claremon DA; Libby BE; Nguyen KT; Pitzenberger SM; Selnick HG; Smith GR; Tebben A; Vacca JP; Varga SL; Agarwal L; Dancheck K; Forsyth AJ; Fletcher DS; Frantz B; Hanlon WA; Harper CF; Hofsess SJ; Kostura M; Lin J; Luell S; O'Neill EA; O'Keefe SJ
J Med Chem; 1999 Jun; 42(12):2180-90. PubMed ID: 10377223
[TBL] [Abstract][Full Text] [Related]
8. Potent inhibitors of the MAP kinase p38.
Henry JR; Rupert KC; Dodd JH; Turchi IJ; Wadsworth SA; Cavender DE; Schafer PH; Siekierka JJ
Bioorg Med Chem Lett; 1998 Dec; 8(23):3335-40. PubMed ID: 9873730
[TBL] [Abstract][Full Text] [Related]
9. Molecular basis for p38 protein kinase inhibitor specificity.
Lisnock J; Tebben A; Frantz B; O'Neill EA; Croft G; O'Keefe SJ; Li B; Hacker C; de Laszlo S; Smith A; Libby B; Liverton N; Hermes J; LoGrasso P
Biochemistry; 1998 Nov; 37(47):16573-81. PubMed ID: 9843424
[TBL] [Abstract][Full Text] [Related]
10. A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase.
Fox T; Coll JT; Xie X; Ford PJ; Germann UA; Porter MD; Pazhanisamy S; Fleming MA; Galullo V; Su MS; Wilson KP
Protein Sci; 1998 Nov; 7(11):2249-55. PubMed ID: 9827991
[TBL] [Abstract][Full Text] [Related]
11. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket.
Tong L; Pav S; White DM; Rogers S; Crane KM; Cywin CL; Brown ML; Pargellis CA
Nat Struct Biol; 1997 Apr; 4(4):311-6. PubMed ID: 9095200
[TBL] [Abstract][Full Text] [Related]
12. p38MAP kinase inhibitors. Part 1: design and development of a new class of potent and highly selective inhibitors based on 3,4-dihydropyrido[3,2-d]pyrimidone scaffold.
Natarajan SR; Wisnoski DD; Singh SB; Stelmach JE; O'Neill EA; Schwartz CD; Thompson CM; Fitzgerald CE; O'Keefe SJ; Kumar S; Hop CE; Zaller DM; Schmatz DM; Doherty JB
Bioorg Med Chem Lett; 2003 Jan; 13(2):273-6. PubMed ID: 12482438
[TBL] [Abstract][Full Text] [Related]
13. p38 kinase inhibitors for the treatment of arthritis and osteoporosis: thienyl, furyl, and pyrrolyl ureas.
Redman AM; Johnson JS; Dally R; Swartz S; Wild H; Paulsen H; Caringal Y; Gunn D; Renick J; Osterhout M; Kingery-Wood J; Smith RA; Lee W; Dumas J; Wilhelm SM; Housley TJ; Bhargava A; Ranges GE; Shrikhande A; Young D; Bombara M; Scott WJ
Bioorg Med Chem Lett; 2001 Jan; 11(1):9-12. PubMed ID: 11140741
[TBL] [Abstract][Full Text] [Related]
14. Pyrimidinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes.
Adams JL; Boehm JC; Kassis S; Gorycki PD; Webb EF; Hall R; Sorenson M; Lee JC; Ayrton A; Griswold DE; Gallagher TF
Bioorg Med Chem Lett; 1998 Nov; 8(22):3111-6. PubMed ID: 9873686
[TBL] [Abstract][Full Text] [Related]
15. Raf-1 is activated by the p38 mitogen-activated protein kinase inhibitor, SB203580.
Kalmes A; Deou J; Clowes AW; Daum G
FEBS Lett; 1999 Feb; 444(1):71-4. PubMed ID: 10037150
[TBL] [Abstract][Full Text] [Related]
16. Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2).
Anderson DR; Meyers MJ; Vernier WF; Mahoney MW; Kurumbail RG; Caspers N; Poda GI; Schindler JF; Reitz DB; Mourey RJ
J Med Chem; 2007 May; 50(11):2647-54. PubMed ID: 17480064
[TBL] [Abstract][Full Text] [Related]
17. Discovery of 3,5-disubstituted-1H-pyrrolo[2,3-b]pyridines as potent inhibitors of the insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase.
Patnaik S; Stevens KL; Gerding R; Deanda F; Shotwell JB; Tang J; Hamajima T; Nakamura H; Leesnitzer MA; Hassell AM; Shewchuck LM; Kumar R; Lei H; Chamberlain SD
Bioorg Med Chem Lett; 2009 Jun; 19(11):3136-40. PubMed ID: 19394223
[TBL] [Abstract][Full Text] [Related]
18. Identification of a membrane Ig-induced p38 mitogen-activated protein kinase module that regulates cAMP response element binding protein phosphorylation and transcriptional activation in CH31 B cell lymphomas.
Swart JM; Bergeron DM; Chiles TC
J Immunol; 2000 Mar; 164(5):2311-9. PubMed ID: 10679065
[TBL] [Abstract][Full Text] [Related]
19. An inhibitor of p38 and JNK MAP kinases prevents activation of caspase and apoptosis of cultured cerebellar granule neurons.
Harada J; Sugimoto M
Jpn J Pharmacol; 1999 Mar; 79(3):369-78. PubMed ID: 10230866
[TBL] [Abstract][Full Text] [Related]
20. A p38 MAP kinase inhibitor SB203580 inhibits CD28-dependent T cell proliferation and IL-2 production.
Ward SG; Parry RV; Matthews J; O'Neill L
Biochem Soc Trans; 1997 May; 25(2):304S. PubMed ID: 9191348
[No Abstract] [Full Text] [Related]
[Next] [New Search]
